Posted by Michael Wonder on 02 Apr 2024
Mirum Pharmaceuticals’ Livmarli (maralixibat oral solution) receives positive reimbursement recommendation by Canada’s CADTH for patients with cholestatic pruritus in Alagille syndrome
2 April 2024 - Positive HTA recommendation for reimbursement signifies an important milestone towards public funding to treat eligible patients with this rare liver disorder.
Mirum Pharmaceuticals today announced that CADTH's Canadian Drug Expert Committee has recommended public reimbursement for Livmarli (maralixibat oral solution) for the treatment of cholestatic pruritus in patients with Alagille syndrome, with certain conditions. This announcement follows Health Canada’s authorisation of Livmarli in this indication in 2023.
